Creative Biolabs provides research-use synthetic phage genome synthesis service to support sequence review, fragment design, DNA synthesis planning, assembly-route selection, clone or construct verification, and rescue feasibility discussion for phage engineering projects. The service is designed for researchers who need a structured route from genome design to assembly-ready material and documentation.
Synthetic phage genome work requires more than ordering DNA fragments. Genome size, repeats, toxic genes, terminal redundancy, packaging signals, host compatibility, and rescue strategy can affect feasibility. We plan these variables before synthesis so that clients receive a practical genome-build roadmap rather than an overpromised result.
Researchers may need synthetic phage genome synthesis when natural template material is unavailable, when defined edits are required, or when a genome must be rebuilt from designed fragments. Early feasibility review is especially important for large tailed phage genomes or sequences that may be unstable in bacterial cloning hosts.
Turn a genome sequence or design brief into a fragment and assembly plan.
Support gene replacement, site-directed changes, or modular genome design.
Compare PCR/Gibson, Golden Gate, yeast recombination, or other project-suitable routes.
Review host, toxicity, genome size, and downstream rebooting constraints.
Our service can include genome design review, oligo or fragment planning, synthesis feasibility assessment, assembly-route selection, cloning strategy, sequencing confirmation, mutation record preparation, and rescue feasibility notes. 100 nt oligo fragments may be used in some builds, PCR amplification can generate assembly fragments, and Gibson assembly, Golden Gate assembly, yeast recombination, in vivo assembly, and in vitro assembly may be considered based on genome size and sequence structure.
Small genomes such as M13 or MS2 under 10 kb may have different design constraints from tailed phage genomes over 20 kb. Standard gene synthesis fragments in the 0.5-5 kb range may be used where feasible, but repeats, cytotoxic sequences, cloning instability, and host compatibility must be reviewed.
Discuss Your Genome Synthesis Plan
We review genome size, topology, repeats, toxic genes, and design intent.
Oligo, PCR, or synthesis fragments are planned with overlaps and junctions.
Assembly strategy is selected based on sequence and host constraints.
In vitro, yeast-based, or other agreed assembly routes are performed where feasible.
Constructs or fragments are checked by sequencing and junction review.
We provide design records, QC data, and optional rescue-feasibility notes.
| Input Type | Useful Details |
|---|---|
| Genome Design | Target sequence, intended edits, genome size, topology, annotation, and required feature changes. |
| Host and Rescue Context | Host strain, rescue system, packaging information, toxicity concerns, and downstream characterization plan. |
| Build Preference | Fragment constraints, assembly method preference, vector requirement, sequencing depth, and biosafety limitations. |
Creative Biolabs can review incomplete designs and suggest what must be clarified before synthesis begins.
Ask About Sequence and Host Inputs
Notes on synthesis risk, assembly route, sequence complexity, and host concerns.
Oligo or fragment architecture, overlap design, and junction plan.
Sequencing or construct confirmation records for synthesized segments or assembled material.
Comments on toxic genes, large genomes, repeats, cloning instability, and rescue-host compatibility.
QC checkpoints include sequence review, synthesis feasibility, assembly-junction confirmation, clone verification, double-stranded sequencing data when scoped, host compatibility review, biosafety documentation, and clear separation of sequence-level construction from functional rescue or biological testing.
Customization can include genome design scope, oligo or fragment length, codon or sequence optimization, PCR/Gibson/Golden Gate route, yeast recombination for larger genomes, cloning vector, rescue-host compatibility review, sequencing depth, site-directed mutagenesis, and documentation level.
A 2025 review in Molecules summarizes the synthetic and functional engineering of bacteriophages and highlights genome assembly and reactivation as central steps. It discusses how phage genome organization, packaging constraints, host compatibility, and assembly routes influence engineering feasibility. Rather than reducing synthetic phage construction to DNA synthesis alone, the review emphasizes that sequence design, fragment architecture, assembly strategy, validation, rescue-host planning, and biosafety assessment collectively determine whether a synthesized genome can support downstream research. Ultimately, it reinforces the need to approach phage engineering as a systematic design-to-validation workflow, not a guaranteed functional rescue.
Fig.1 Phage engineering strategies and applications.1
Q: What information is needed to start a synthetic phage genome synthesis project?
A: We usually need the genome sequence or design brief, genome size and topology, intended edits, host or rescue system information, biosafety constraints, and downstream goal.
Q: Can you synthesize large tailed phage genomes?
A: Large genomes can be reviewed for feasibility, but build strategy depends on repeats, toxic genes, fragment stability, assembly route, and rescue-host compatibility.
Q: Do you support both in vitro and yeast-based assembly?
A: Yes. We can discuss PCR/Gibson, Golden Gate, yeast recombination, in vivo assembly, or other suitable routes based on the sequence and project goal.
Q: Does synthesis guarantee functional phage rescue?
A: No. Sequence-level synthesis or assembly does not guarantee rescue, propagation, or biological activity. Functional rescue must be scoped and assessed separately.
Q: What deliverables are included?
A: Deliverables may include a feasibility summary, fragment map, assembly plan, sequencing data, mutation record, cloning notes, and risk comments for host compatibility or cytotoxicity.
Q: Can you support site-directed mutagenesis in a synthetic genome?
A: Yes. Defined mutations, insertions, deletions, or modular changes can be reviewed and incorporated into the design when sequence and assembly constraints allow.
Reference:
Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Creative Biolabs is a globally recognized phage company. Creative Biolabs is committed to providing researchers with the most reliable service and the most competitive price.
